Evidence map›Paper›PMID 31139757›Full record

ReviewHealth science reports2019

Natural history of human papillomavirus and vaccinations in men: A literature review.

Benjamin J Lieblong, Brooke E E Montgomery, L Joseph Su, Mayumi Nakagawa

Open access · goldAbstract readReview
In one paragraph

Review in Health science reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. 1α,25(OH)Bioengineered · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Benjamin J LieblongCollege of Medicine, Department of Pathology University of Arkansas for Medical Sciences Little Rock Arkansas USA.ORCID https://orcid.org/0000-0001-7225-7049
Brooke E E MontgomeryFaye W. Boozman College of Public Health, Department of Health Behavior and Health Education University of Arkansas for Medical Sciences Little Rock Arkansas USA.ORCID https://orcid.org/0000-0002-3316-8665
L Joseph SuFaye W. Boozman College of Public Health, Department of Epidemiology University of Arkansas for Medical Sciences Little Rock Arkansas USA.ORCID https://orcid.org/0000-0002-4332-2363
Mayumi NakagawaCollege of Medicine, Department of Pathology University of Arkansas for Medical Sciences Little Rock Arkansas USA.ORCID https://orcid.org/0000-0002-0377-4613
University of Arkansas for Medical Sciences · USArkansas Department of Health · US

Funding

Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-RenewalR01CA143130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAKAGAWA, MAYUMI · 2010 to 2025
$10.0M
NCI NIH HHS R01 CA143130
6 · The paper itself

Abstract

BACKGROUND AND

aimsInfection with high-risk (HR) genotypes of the human papillomavirus (HPV) is necessary for and causative of almost all cervical cancers and their precursor condition, cervical intraepithelial neoplasia. These conditions have been sharply reduced by cervical cytology screening, and a further decrease is expected because of the recent introduction of prophylactic HPV vaccinations. While significant attention has been given to gynecologic HPV disease, men can be affected by HPV-related cancers of the anus, penis, and oropharynx. This literature review aims to address disparities in HPV-related disease in men, and certain HR male subpopulations, compared with women. DISCUSSION: Overall, immunocompetent men are far less likely than women to develop anogenital HPV-related cancers, despite harboring HR HPV infections at anogenital sites. On the other hand, men who have sex with men and men living with human immunodeficiency virus infection are at considerably higher risk of HPV-related disease. Historic rates of prophylactic HPV vaccination in males have trailed those of females due to numerous multilevel factors, although, in recent years, this sex gap in vaccination coverage has been closing. In the absence of routine HPV screening in males, therapeutic vaccinations have emerged as a potential treatment modality for preinvasive neoplasia and are in various phases of clinical testing.

conclusionSuccessful reductions in HPV disease morbidity at the population level must acknowledge and target HPV infections in men.

Indexed as

human papillomavirusmenprophylactic vaccinationtherapeutic vaccination

Identifiers

PMID31139757
PMCPMC6529831
OpenAlexW2921473695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.